Group items tagged

The OPORP Orthotics and Prosthetics Outcomes Research Award (OPORA) is being offered for the first time in FY14. It is intended to support research that evaluates the comparative effectiveness of and functional outcomes associated with prosthetic and orthotic clinical interventions and/or other rehabilitation interventions for Service Members and Veterans who have undergone limb salvage or limb amputation. The goal is to improve our understanding of and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers. Proposed projects should be designed to provide outcomes data regarding orthotic and prosthetic devices, and/or related clinical interventions and must include the anticipated effect on patient care metrics. Collaboration with military researchers and clinicians is encouraged, as are joint Department of Defense (DoD)-VA studies, including longitudinal outcome studies. Studies are sought that: * Compare different patient care approaches. * Include patient-centric outcome assessments. * Have the potential to generate new knowledge that can be developed into new clinical practice guidelines, and/or new prescription algorithms for prosthetic and orthotic devices. * Have the potential to develop new technology for improved prosthetic and orthotic devices, therefore improving patient outcomes. * Provide information on quality of life, reintegration, and/or return to duty/return to work as it pertains to those patients who use a prosthetic or orthotic device due to limb trauma. All applications must demonstrate direct relevance to Service Members and Veterans with traumatic extremity injury and/or amputation using prosthetics and orthotic devices. Examples of studies that are appropriate for submission to the FY14 OPORA include, but are not limited to, examination of the

Pandemics have far reaching consequences that range from deaths to shutting down the economy as we have witnessed during the recent COVID19 crisis. Hence there is a need to be better prepared for such pandemics. We need to solve problems ranging from predictive analytics innovative devices for saving lives to technology for devising voting machines. The social and economic impact for the above areas is huge and some of the work can be transformative and save lives. Areas of interest to us include, but are not limited to: - Mathematical models for spread and the impact of pandemics. - Scalable simulation techniques for pandemics (e.g. with multi agents). - Biomedical/Nano sensor devices for detecting symptoms and agents. - Algorithms for rapid exploration of the drug screening and discovery workflows (e.g. use reinforcement learning) - Advanced computational biology techniques for sequencing, detecting viral evolution (e.g. in COVID-19). - Algorithms and systems for contact tracing (with privacy preserving). - Algorithms and recommendation systems for curating media and news. - Collaboration techniques for more effective health, and efficiency during pandemics. Improved identity and security techniques. - Distributed Ledgers, their applications and their governance for and during pandemics. - Pandemic data science - understanding the patterns and the impact of a pandemic like COVID-10. Creation of curated data sets. We are interested in both the science and technology aspects of these problem sets, and, particularly, in the intersections between them.

The intent of the FY17 ERP IDA is to solicit research to understand the magnitude and underlying mechanisms of PTE. The FY17 ERP IDA offers two levels of funding. Funding Level I is intended to support high-risk or high-gain research from Principal Investigators (PIs) at or above the level of a postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent). Note that PIs submitting Funding Level I applications will be required to verify their eligibility for this award. Funding Level II is intended to support a more mature, hypothesis-driven research project. To be considered for an FY17 ERP IDA Funding Level II, the PI must be an independent investigator at or above the level of Assistant Professor (or equivalent). While not required, applications to either Funding Level I or II should provide relevant preliminary data. Preliminary data for either Funding Level may come from the PI's published work, pilot data, or from peer-reviewed literature. The requested budget level should be appropriate for the scope of research proposed.For Funding Level I:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $300,000. The maximum period of performance is 2 years. For Funding Level II:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $500,000. The maximum period of performance is 3 years. FY17 ERP IDA Focus Areas: The research impact for the FY17 ERP IDA is expected to benefit the military, Veteran, and civilian communities.

The primary purpose of the ASRM and SREI Research Grant Programs is to provide funds for new investigators to establish independent research programs. New investigators are those who have completed their training within the past three years and have independent faculty appointments at the commencement of the research. In special cases, ASRM will consider applications for bridge funding (i.e., between grant funding periods) for projects that are of benefit to other members of the Society, or for funding of new, highly innovative research projects by established investigators. Both the ASRM Research Grants, which are funded by the ASRM, and the SREI Research Grants, which are funded by SREI, are reviewed by the ASRM Research Committee. Grants in amounts of $10,000 to $50,000 will be considered for funding by the ASRM Board of Directors on an annual basis. A total of $200,000 is available for 2016. The SREI Board of Directors will fund one grant of up to $40,000. Funds are available for project expenses, technical assistance, patient expenses, research supplies and durable laboratory equipment. Up to ten percent (10%) of funds may be used for indirect costs or institutional overhead in circumstances deemed to be extraordinary by the Research Committee. Research grant funds may be expended over a 2-year time interval. If residual funds remain after 2 years, the principal investigator can apply for a no-cost extension. An individual should indicate which grant(s) he/she is applying for though he/she is eligible to receive only one grant.

The Long Term Research in Environmental Biology (LTREB) Program supports the generation of extended time series of data to address important questions in evolutionary biology, ecology, and ecosystem science. Research areas include, but are not limited to, the effects of natural selection or other evolutionary processes on populations, communities, or ecosystems; the effects of interspecific interactions that vary over time and space; population or community dynamics for organisms that have extended life spans and long turnover times; feedbacks between ecological and evolutionary processes; pools of materials such as nutrients in soils that turn over at intermediate to longer time scales; and external forcing functions such as climatic cycles that operate over long return intervals. The Program intends to support decadal projects. Funding for an initial, 5-year period requires submission of a preliminary proposal and, if invited, submission of a full proposal that includes a 15-page project description. Proposals for the second five years of support (renewal proposals) are limited to an eight-page project description and do not require a preliminary proposal. Continuation of an LTREB project beyond an initial ten year award will require submission of a new preliminary proposal that presents a new decadal research plan.?? Successful LTREB proposals address three essential components: A Decadal Research Plan that clearly articulates important questions that cannot be addressed with data that have already been collected, but could be answered if ten additional years of data were collected. This plan is not a research timeline or management plan. It is a concise justification for ten additional years of support in order to advance understanding of key concepts, questions, or theories in environmental biology.Core Data: LTREB proposals require that the author has studied a particular phenomenon or process for at least six years up to the present or for long enough to gene

We envision that studies funded by this Research RFP will fall into one the following key areas: · Studies focused on the molecular and biochemical mechanisms regulating SMN expression or mediating SMN function. Results should lead to a better understanding of the requirements for SMN protein biologically. There is a particular interest in identifying genetic modifiers, upstream regulators of SMN expression / splicing / function, and downstream effectors of SMN functional activity, resulting in new drug targets for SMA. · Studies resulting in greater understanding of the pathophysiology of SMA, using well-validated animal or cellular models of the SMA. This includes focus on the tissue or timing requirements for SMN protein, the cellular autonomy of the disease in motor neurons and other cells, peripheral versus central manifestations of SMA, and others. · Studies focused on early proof-of concept assessment of novel therapeutic approaches for SMA in well-validated animal or cellular models of the disease or on progressing aspects of ongoing preclinical drug programs for SMA towards IND. Proposed SMN enhancing approaches should have advantage over current candidates or have the ability to be used in combination. Particular interest exists in non-SMN based approaches with the potential for combination use with SMN up-regulation strategies. · Work focused on generating research or clinical trial tools for SMA, such as new animal models, phenotypic cellular assays, activity assays for SMN function, biomarkers or outcome measures for clinical trials, and newborn screening protocols / technologies.

This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. The scientific scope of this FOA includes: · Development and optimization of QI tools and/or methods for treatment planning, predicting or measuring response to therapy as open source tools that will translate into clinical trial decision support; · Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing single-site or multi-site clinical trials. A phased approach that emphasizes each of these activities must be proposed. Investigators must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development and optimization of QI tools and methods chosen for study by the investigating team, while the UH3 phase is for the validation of the tools/methods developed in the UG3 phase. The UG3 phase can be no more than 2 years in duration, and the total project cannot exceed 5 years. At completion, UG3 projects will be reviewed by program staff. Those that have met their milestones may be administratively considered by NCI program staff for transition to the UH3 validation phase.

Biological and Environmental Research (BER) of the Office of Science (SC), U.S. Department of Energy (DOE) hereby announces its interest in receiving applications for research of interest to the Genomic Science Program (http://genomicscience.energy.gov) in the following research areas: a) Integrating large-scale systems biology data to model, design, and engineer microbial systems for the production of biofuels and bioproducts: Interdisciplinary approaches to develop innovative, high-throughput modeling, genome-wide design and editing, and engineering technologies for a broad range of microbes relevant for the production of biofuels and bioproducts from biomass. b) Plant systems design for bioenergy: To develop novel technologies for genome-scale engineering to re-design bioenergy crops that can grow in marginal environments while producing high yield of biomass that can be easily converted to biofuels and bioproducts. Applications should include strategies to address biocontainment, minimizing risks of potential release of engineered organisms into the environment or other unintended outcomes.

Biological and Environmental Research (BER) of the Office of Science (SC), U.S. Department of Energy (DOE) hereby announces its interest in receiving applications for research of interest to the Genomic Science Program (http://genomicscience.energy.gov) in the following research areas: a) Integrating large-scale systems biology data to model, design, and engineer microbial systems for the production of biofuels and bioproducts: Interdisciplinary approaches to develop innovative, high-throughput modeling, genome-wide design and editing, and engineering technologies for a broad range of microbes relevant for the production of biofuels and bioproducts from biomass. b) Plant systems design for bioenergy: To develop novel technologies for genome-scale engineering to re-design bioenergy crops that can grow in marginal environments while producing high yield of biomass that can be easily converted to biofuels and bioproducts. Applications should include strategies to address biocontainment, minimizing risks of potential release of engineered organisms into the environment or other unintended outcomes.

The participating NIH Institutes and Centers invite Research Project Grant (R01) applications to develop assays for high throughput screening (HTS) for use in Probe and Pre-therapeutic Discovery. Through this FOA, NIH wishes to stimulate research in 1) developing assays for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; and 2) establishing collaboration with screening centers that have the requisite expertise and experience needed in implementation of HTS assays for the discovery and development of small molecule chemical probes. This FOA seeks to establish a stream of scientifically and technologically outstanding assays for screening by the NIH Molecular Libraries Production Centers Network (MLPCN) in the Molecular Libraries Program (MLP) and other academic centers. One important criterion for this initiative is novelty, so applicants are therefore encouraged to avoid focusing on areas and approaches that have been extensively targeted in other settings. Assays should be relevant to the scope of research in at least one of the participating NIH Institutes.

JDRF is launching an initiative to overcome challenges for increased longevity for delivery of insulin via sub-cutaneous infusion. Components include infusion sets and cannula used in patch pumps. Based on these EOIs, potential applications will be subsequently invited to be developed and submitted as full proposal. In this call, JDRF intends to fund innovative approaches to identifying the fundamental mechanism of failure and/or provide mitigations to known failure modes when delivering insulin via sub-cutaneous cannula. The immediate aim is to increase the reliability of insulin infusion, with an ultimate aim to extend the wear duration of infusion sets and patch pumps to match the wear duration of CGMs, for the majority of people with T1D. The objective of this initiative is to identify common mechanisms of failure, or demonstrate effective mitigation of known failure mechanisms, in continuous sub-cutaneous insulin infusion. Examples of mechanisms of failure discovery may include, but are not limited to: * ECM or other protein deposition * Inflammation and wound healing process * Fibrosis * Tissue Granulation Examples of mitigations for known failure modes may include: * Drug eluting materials * Cannula Coatings or Surface treatments * Insulin Excipients Discovery proposals must have a clear pathway to commercial viability, and particular emphasis will be given to novel mechanisms of mitigation. Evaluations of proposed mitigations will require preliminary evidence of an underlying mechanism to be addressed. MECHANISM Successful EOIs from for profit entities would be invited under our Industry Development and Discovery Program mechanism1. Applications from nonprofit organizations, public and private universities, colleges, hospitals, laboratories, units of state and local governments would be invited under our Strategic Research Agreement mechanism2. Projects should request costs commen

This Notice supersedes NOT-OD-15-024 about the NIH and AHRQ requirement for use of a new biosketch format and provides some latitude in the transition for those who have already been compiling biosketches for their large grant applications with deadlines in early in 2015. NIH and AHRQ encourages applicants to use the newly published biosketch format for all grant and cooperative agreement applications submitted for due dates on or after January 25, 2015, and will require use of the new format for applications submitted for due dates on or after May 25, 2015. Applicants may submit using the new biosketch format for due dates before January 25, 2015, if they wish.

The SCIMS program is designed to provide a multidisciplinary system of rehabilitation care specifically to meet the needs of individuals with SCI. To be eligible for a SCI Model Systems grant, an applicant institution must encompass a continuum of care for people with SCI, including emergency medical services, acute care services, acute medical rehabilitation services, and post-acute services. For purposes of this program, SCI is defined as a clinically discernible degree of neurologic impairment of the spinal cord following a traumatic event. NIDILRR currently supports 14 SCIMS centers through this program. The funding for these Centers is primarily used to conduct SCI research and to collect and send data to the SCIMS longitudinal database. SCIMS Centers will be funded at varying amounts up to the maximum award based on the numbers of subjects eligible for follow-up in the existing SCIMS longitudinal database. Existing centers with significantly larger numbers of subjects will receive higher funding within the specified range, as determined by NIDILRR after the applicant is selected for funding. Applicants provide detailed budgets for each research project and for data collection costs associated with the longitudinal database. Funding will be determined individually for each successful applicant, up to the maximum allowed, based upon the documented workload associated with the follow-up data collection, the other costs of the grant, and the overall budgetary limits of the program

In recent years, somatic cells as therapeutic agents have provided new treatment approaches for a number of pathological conditions that were deemed untreatable, or difficult to treat. Several successful cell therapies using T cells have been demonstrated for cancer and autoimmune diseases, while stem cell therapies have given relief for heart disease and stroke. Hundreds of clinical trials are ongoing to examine efficacy of cell therapies for a variety of other diseases including diabetes, Alzheimer's, Parkinson's, and Crohn's disease. Production of therapeutic cells is currently expensive and, therefore, cost prohibitive for the large number of people who might benefit from these treatments. The overarching goal of this Advanced Biomanufacturing of Therapeutic Cells (ABTC) solicitation is to catalyze well-integrated interdisciplinary research to understand, design, and control cell manufacturing systems and processes that will enable reproducible, cost-effective, and high-quality production of cells with predictable performance for the identified therapeutic function.

In recent years, somatic cells as therapeutic agents have provided new treatment approaches for a number of pathological conditions that were deemed untreatable, or difficult to treat. Several successful cell therapies using T cells have been demonstrated for cancer and autoimmune diseases, while stem cell therapies have given relief for heart disease and stroke. Hundreds of clinical trials are ongoing to examine efficacy of cell therapies for a variety of other diseases including diabetes, Alzheimer's, Parkinson's, and Crohn's disease. Production of therapeutic cells is currently expensive and, therefore, cost prohibitive for the large number of people who might benefit from these treatments. The overarching goal of this Advanced Biomanufacturing of Therapeutic Cells (ABTC) solicitation is to catalyze well-integrated interdisciplinary research to understand, design, and control cell manufacturing systems and processes that will enable reproducible, cost-effective, and high-quality production of cells with predictable performance for the identified therapeutic function.

This Funding Opportunity Announcement (FOA) issued by the Fogarty International Center (FIC) seeks to stimulate innovative ideas and impactful research to better understand the complexities around developing appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for HIV-associated non-communicable diseases (NCDs) in Low and Middle-Income Countries (LMICs). Specifically, this initiative will support research in the following areas: a) Basic sciences to address etiopathogenesis of NCDs in Persons Living with HIV (PLWH); b) Aging process in PLWH; c) Diagnostics tools for early detection of NCDs in PLWH; d) Therapeutic interventions to explore optimal drug regimens for PLWH with NCDs; e) Behavioral studies for better quality of life of PLWH with NCDs; and f) Clinical studies for better patient centered care for PLWH with NCDs. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development and assessing feasibility of the proposed studies (https://grants.nih.gov/grants/funding/r21.htm ). It is hoped that this preliminary research will lay the foundation for larger studies that can lead to applications to other organizations or NIH institutes that support HIV-associated NCD research.

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds thorough the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will not support animal studies to prove efficacy of the candidate compound unless required by the Food and Drug Administration or peer review. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

Biophotonics applies photonics technology to the fields of medicine, biology and biotechnology.  Basic research and innovation in photonics that is very fundamental in science and engineering is needed to lay the foundation for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies.  Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening.  Low cost and minimally invasive medical diagnostics and therapies are key goals. Examples of topics are: Macromolecule Markers - Innovative methods for labeling of macromolecules, new compositions of matter/methods of fabrication of multi-color probes such as might be used for marking and detection of specific pathological cells and push the envelope of optical sensing to the limits of detection, resolution, and identification Low Coherence Sensing at the Nanoscale - Low coherence enhanced backscattering (LEBS), n-dimensional elastic light scattering, and angle-resolved low coherence interferometry for early cancer detection (dysplasia) Neurophotonics - Studies of photon activation of neurons at the interface of nanomaterials attached to cells.  Development and application of biocompatible photonic tools such as parallel interfaces and interconnects for communicating and control of neural networks Micro- and Nano-photonic - Development and application of nanoparticle fluorescent quantum-dots; sensitive, multiplexed, high-throughput characterization of macromolecular properties of cells; nanomaterials and nanodevices for biomedicine Optogenetics - Employing light-activated channels and enzymes for manipulation of neural activity with temporal precision. 

Biophotonics applies photonics technology to the fields of medicine, biology and biotechnology.  Basic research and innovation in photonics that is very fundamental in science and engineering is needed to lay the foundation for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies.  Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening.  Low cost and minimally invasive medical diagnostics and therapies are key goals. Examples of topics are: Macromolecule Markers - Innovative methods for labeling of macromolecules, new compositions of matter/methods of fabrication of multi-color probes such as might be used for marking and detection of specific pathological cells and push the envelope of optical sensing to the limits of detection, resolution, and identification Low Coherence Sensing at the Nanoscale - Low coherence enhanced backscattering (LEBS), n-dimensional elastic light scattering, and angle-resolved low coherence interferometry for early cancer detection (dysplasia) Neurophotonics - Studies of photon activation of neurons at the interface of nanomaterials attached to cells.  Development and application of biocompatible photonic tools such as parallel interfaces and interconnects for communicating and control of neural networks Micro- and Nano-photonic - Development and application of nanoparticle fluorescent quantum-dots; sensitive, multiplexed, high-throughput characterization of macromolecular properties of cells; nanomaterials and nanodevices for biomedicine Optogenetics - Employing light-activated channels and enzymes for manipulation of neural activity with temporal precision. 

This FOA encourages Research Project Grant (R01) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions.The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

This FOA encourages Research Project Grant (R01) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions.The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

This Funding Opportunity Announcement (FOA) invites training grant applications for support of predoctoral and postdoctoral training for research careers in biomedical informatics and data science. Applications may be for the creation of entirely new programs or for the renewal of active NLM T15 training grants. Such training helps meet the growing need for investigators trained in biomedical computing, data science and related information fields as they directly relate to application domains in health and biomedicine, including health care delivery, basic biomedical research, clinical and translational research, public health and similar areas.

This Funding Opportunity Announcement (FOA) invites training grant applications for support of predoctoral and postdoctoral training for research careers in biomedical informatics and data science. Applications may be for the creation of entirely new programs or for the renewal of active NLM T15 training grants. Such training helps meet the growing need for investigators trained in biomedical computing, data science and related information fields as they directly relate to application domains in health and biomedicine, including health care delivery, basic biomedical research, clinical and translational research, public health and similar areas.